Systemic administration of BMP7 in breast cancer mouse models has proven to significantly inhibit bone metastases originating from human prostate and breast cancer, by reducing TGFβ-dependent SMAD3/4 activation, activating nuclear signaling of SMAD1/4/5, and restoring E-cadherin levels. The gene discussed is SMAD1; the disease is breast carcinoma.